Literature DB >> 4005333

Daytime alertness in subjective and objective insomnia: some preliminary findings.

J L Sugerman, J A Stern, J K Walsh.   

Abstract

Daytime performance and alertness were examined in two groups of patients with disorders of initiating and maintaining sleep (DIMS) and a control group of self-described good sleepers. Individuals complaining of disturbed sleep that was verified by polysomnographic indices (objective DIMS) and a group with complaints of disturbed sleep in the absence of objective findings (subjective DIMS) were compared with normal sleepers. Nocturnal polysomnographic recordings documented increased sleep latencies and decreased sleep efficiencies for the objective DIMS group and essentially normal sleep for the subjective DIMS group. However, the subjective DIMS group showed impaired daytime vigilance compared with both the objective DIMS and control groups. Additionally, the subjective DIMS group demonstrated an atypical daytime alertness and a tendency toward lowered arousal during vigilance task performance. Insomniacs without clear objective findings of disturbed sleep, therefore, showed decrements commonly seen following sleep loss or sleep disturbance, whereas insomniacs with evidence of disturbed nocturnal sleep did not differ from the control group in terms of waking function.

Entities:  

Mesh:

Year:  1985        PMID: 4005333     DOI: 10.1016/0006-3223(85)90153-2

Source DB:  PubMed          Journal:  Biol Psychiatry        ISSN: 0006-3223            Impact factor:   13.382


  19 in total

1.  Insomnia with Short Sleep Duration: Nosological, Diagnostic, and Treatment Implications.

Authors:  Alexandros N Vgontzas; Julio Fernandez-Mendoza
Journal:  Sleep Med Clin       Date:  2013-09-01

Review 2.  Insomnia and its impact on physical and mental health.

Authors:  Julio Fernandez-Mendoza; Alexandros N Vgontzas
Journal:  Curr Psychiatry Rep       Date:  2013-12       Impact factor: 5.285

3.  Epidemiological and clinical relevance of insomnia diagnosis algorithms according to the DSM-IV and the International Classification of Sleep Disorders (ICSD).

Authors:  Maurice M Ohayon; Charles F Reynolds
Journal:  Sleep Med       Date:  2009-10       Impact factor: 3.492

Review 4.  Insomnia with objective short sleep duration: the most biologically severe phenotype of the disorder.

Authors:  Alexandros N Vgontzas; Julio Fernandez-Mendoza; Duanping Liao; Edward O Bixler
Journal:  Sleep Med Rev       Date:  2013-02-16       Impact factor: 11.609

5.  Predicting Attentional Impairment in Women With Posttraumatic Stress Disorder Using Self-Reported and Objective Measures of Sleep.

Authors:  Kimberly B Werner; Kimberly A Arditte Hall; Michael G Griffin; Tara E Galovski
Journal:  J Clin Sleep Med       Date:  2019-09-15       Impact factor: 4.062

6.  MSLT in primary insomnia: stability and relation to nocturnal sleep.

Authors:  Timothy A Roehrs; Surilla Randall; Erica Harris; Renee Maan; Thomas Roth
Journal:  Sleep       Date:  2011-12-01       Impact factor: 5.849

Review 7.  (Mis)perception of sleep in insomnia: a puzzle and a resolution.

Authors:  Allison G Harvey; Nicole K Y Tang
Journal:  Psychol Bull       Date:  2011-10-03       Impact factor: 17.737

8.  Does physiological hyperarousal enhance error rates among insomnia sufferers?

Authors:  Jack D Edinger; Melanie K Means; Andrew D Krystal
Journal:  Sleep       Date:  2013-08-01       Impact factor: 5.849

Review 9.  Sleep: important considerations for the prevention of cardiovascular disease.

Authors:  Michael A Grandner; Pamela Alfonso-Miller; Julio Fernandez-Mendoza; Safal Shetty; Sundeep Shenoy; Daniel Combs
Journal:  Curr Opin Cardiol       Date:  2016-09       Impact factor: 2.161

10.  Daytime symptoms in primary insomnia: a prospective analysis using ecological momentary assessment.

Authors:  Daniel J Buysse; Wesley Thompson; John Scott; Peter L Franzen; Anne Germain; Martica Hall; Douglas E Moul; Eric A Nofzinger; David J Kupfer
Journal:  Sleep Med       Date:  2007-03-23       Impact factor: 3.492

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.